TY - JOUR
T1 - Genome-wide association study of response to cognitive-behavioural therapy in children with anxiety disorders
AU - Coleman, Jonathan R I
AU - Lester, Kathryn J.
AU - Keers, Robert
AU - Roberts, Susanna
AU - Curtis, Charles
AU - Arendt, Kristian
AU - Bögels, Susan
AU - Cooper, Peter
AU - Creswell, Cathy
AU - Dalgleish, Tim
AU - Hartman, Catharina A.
AU - Heiervang, Einar R.
AU - Hötzel, Katrin
AU - Hudson, Jennifer L.
AU - In-Albon, Tina
AU - Lavallee, Kristen
AU - Lyneham, Heidi J.
AU - Marin, Carla E.
AU - Meiser-Stedman, Richard
AU - Morris, Talia
AU - Nauta, Maaike H.
AU - Rapee, Ronald M.
AU - Schneider, Silvia
AU - Schneider, Sophie C.
AU - Silverman, Wendy K.
AU - Thastum, Mikael
AU - Thirlwall, Kerstin
AU - Waite, Polly
AU - Wergeland, Gro Janne
AU - Breen, Gerome
AU - Eley, Thalia C.
N1 - Copyright the Author(s) 2016. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Background Anxiety disorders are common, and cognitive-behavioural therapy (CBT) is a first-line treatment. Candidate gene studies have suggested a genetic basis to treatment response, but findings have been inconsistent. Aims To perform the first genome-wide association study (GWAS) of psychological treatment response in children with anxiety disorders (n = 980). Method Presence and severity of anxiety was assessed using semistructured interview at baseline, on completion of treatment (post-treatment), and 3 to 12 months after treatment completion (follow-up). DNA was genotyped using the Illumina Human Core Exome-12v1.0 array. Linear mixed models were used to test associations between genetic variants and response (change in symptom severity) immediately post-treatment and at 6-month follow-up. Results No variants passed a genome-wide significance threshold (P<5×10-8) in either analysis. Four variants met criteria for suggestive significance (P=5×10-6) in association with response post-treatment, and three variants in the 6-month follow-up analysis. Conclusions This is the first genome-wide therapygenetic study. It suggests no common variants of very high effect underlie response to CBT. Future investigations should maximise power to detect single-variant and polygenic effects by using larger, more homogeneous cohorts.
AB - Background Anxiety disorders are common, and cognitive-behavioural therapy (CBT) is a first-line treatment. Candidate gene studies have suggested a genetic basis to treatment response, but findings have been inconsistent. Aims To perform the first genome-wide association study (GWAS) of psychological treatment response in children with anxiety disorders (n = 980). Method Presence and severity of anxiety was assessed using semistructured interview at baseline, on completion of treatment (post-treatment), and 3 to 12 months after treatment completion (follow-up). DNA was genotyped using the Illumina Human Core Exome-12v1.0 array. Linear mixed models were used to test associations between genetic variants and response (change in symptom severity) immediately post-treatment and at 6-month follow-up. Results No variants passed a genome-wide significance threshold (P<5×10-8) in either analysis. Four variants met criteria for suggestive significance (P=5×10-6) in association with response post-treatment, and three variants in the 6-month follow-up analysis. Conclusions This is the first genome-wide therapygenetic study. It suggests no common variants of very high effect underlie response to CBT. Future investigations should maximise power to detect single-variant and polygenic effects by using larger, more homogeneous cohorts.
UR - http://www.scopus.com/inward/record.url?scp=84988810010&partnerID=8YFLogxK
U2 - 10.1192/bjp.bp.115.168229
DO - 10.1192/bjp.bp.115.168229
M3 - Article
C2 - 26989097
AN - SCOPUS:84988810010
SN - 0007-1250
VL - 209
SP - 236
EP - 243
JO - British Journal of Psychiatry
JF - British Journal of Psychiatry
IS - 3
ER -